Ethambutol optimal clinical dose and susceptibility breakpoint identification by use of a novel pharmacokinetic-pharmacodynamic model of disseminated intracellular Mycobacterium avium

Antimicrobial Agents and Chemotherapy

Volumn 54, Issue 5, 2010, Pages 1728-1733

  Deshpande, Devyani ^a   Srivastava, Shashikant ^a   Meek, Claudia ^b   Leff, Richard ^b   Gumbo, Tawanda ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ETHAMBUTOL;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERICIDAL ACTIVITY; COLONY FORMING UNIT; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; EXTRACELLULAR MATRIX; HOLLOW FIBER; HUMAN; HUMAN CELL; INTRACELLULAR BACTERIUM; MACROPHAGE; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; MONTE CARLO METHOD; MYCOBACTERIUM AVIUM; NONHUMAN; OPTIMAL DRUG DOSE; OUTCOME ASSESSMENT; PHARMACODYNAMICS; PHARMACOLOGICAL PARAMETERS; PRIORITY JOURNAL; TIME TO MAXIMUM PLASMA CONCENTRATION;

ANTITUBERCULAR AGENTS; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, MICROBIAL; ETHAMBUTOL; HUMANS; MACROPHAGES; MICROBIAL SENSITIVITY TESTS; MODELS, BIOLOGICAL; MONTE CARLO METHOD; MYCOBACTERIUM AVIUM; MYCOBACTERIUM AVIUM-INTRACELLULARE INFECTION;

EID: 77951213496     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01355-09     Document Type: Article

References (45)

1. Albert, R. K., J. A. Sbarbaro, L. D. Hudson, and M. Iseman. 1976. High-dose ethambutol: its role in intermittent chemotherapy. A six-year study. Am. Rev. Respir. Dis. 114:699-704.
2. Ambrose, P. G. 2006. Monte Carlo simulation in the evaluation of susceptibility breakpoints: predicting the future: insights from the society of infectious diseases pharmacists. Pharmacotherapy 26:129-134.
3. Ambrose, P. G., S. M. Bhavnani, C. M. Rubino, A. Louie, T. Gumbo, A. Forrest, and G. L. Drusano. 2007. Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it's not just for mice anymore. Clin. Infect. Dis. 44:79-86.
4. Ambrose, P. G., A. K. Meagher, J. A. Passarell, S. A. Van Wart, B. B. Cirincione, S. M. Bhavnani, and E. Ellis-Grosse. 2009. Application of patient population-derived pharmacokinetic-pharmacodynamic relationships to tigecycline breakpoint determination for staphylococci and streptococci. Diagn. Microbiol. Infect. Dis. 63:155-159.
5. Anonymous. 2001. First randomised trial of treatments for pulmonary disease caused by M avium intracellulare, M malmoense, and M xenopi in HIV negative patients: rifampicin, ethambutol and isoniazid versus rifampicin and ethambutol. Thorax 56:167-172.
6. Blaser, J., B. B. Stone, and S. H. Zinner. 1985. Efficacy of intermittent versus continuous administration of netilmicin in a two-compartment in vitro model. Antimicrob. Agents Chemother. 27:343-349.
7. Blaser, J., B. B. Stone, and S. H. Zinner. 1985. Two compartment kinetic model with multiple artificial capillary units. J. Antimicrob. Chemother. 15(Suppl. A):131-137.
8. Chaisson, R. E., J. E. Gallant, J. C. Keruly, and R. D. Moore. 1998. Impact of opportunistic disease on survival in patients with HIV infection. AIDS 12:29-33.
9. Chaisson, R. E., P. Keiser, M. Pierce, W. J. Fessel, J. Ruskin, C. Lahart, C. A. Benson, K. Meek, N. Siepman, and J. C. Craft. 1997. Clarithromycin and ethambutol with or without clofazimine for the treatment of bacteremic Mycobacterium avium complex disease in patients with HIV infection. AIDS 11:311-317.
10. Chaisson, R. E., R. D. Moore, D. D. Richman, J. Keruly, and T. Creagh. 1992. Incidence and natural history of Mycobacterium avium-complex infections in patients with advanced human immunodeficiency virus disease treated with zidovudine. The Zidovudine Epidemiology Study Group. Am. Rev. Respir. Dis. 146:285-289.
11. Clinical and Laboratory Standards Institute. 2003. Susceptibility testing of mycobacteria, nocardiae, and other aerobic actinomycetes. Approved standard. Clinical and Laboratory Standards Institute, Wayne, PA.
12. Conte, J. E., Jr., J. A. Golden, J. Kipps, E. T. Lin, and E. Zurlinden. 2001. Effects of AIDS and gender on steady-state plasma and intrapulmonary ethambutol concentrations. Antimicrob. Agents Chemother. 45:2891-2896.
13. D'Argenio, D. Z., and A. Schumitzky. 1997. ADAPT II. A program for simulation, identification, and optimal experimental design. User manual. Biomedical Simulations Resource. University of Southern California, Los Angeles, CA.
14. Dube, M. P., F. R. Sattler, F. J. Torriani, D. See, D. V. Havlir, C. A. Kemper, M. G. Dezfuli, S. A. Bozzette, A. E. Bartok, J. M. Leedom, J. G. Tilles, and J. A. McCutchan. 1997. A randomized evaluation of ethambutol for prevention of relapse and drug resistance during treatment of Mycobacterium avium complex bacteremia with clarithromycin-based combination therapy. California Collaborative Treatment Group. J. Infect. Dis. 176:1225-1232.
15. Eum, S. Y., J. H. Kong, M. S. Hong, Y. J. Lee, J. H. Kim, S. H. Hwang, S. N. Cho, L. E. Via, and C. E. Barry III. 2010. Neutrophils are the predominant infected phagocytic cells in the airways of patients with active pulmonary TB. Chest 137:122-128.
16. Gordin, F. M., P. M. Sullam, S. D. Shafran, D. L. Cohn, B. Wynne, L. Paxton, K. Perry, and C. R. Horsburgh, Jr. 1999. A randomized, placebo-controlled study of rifabutin added to a regimen of clarithromycin and ethambutol for treatment of disseminated infection with Mycobacterium avium complex. Clin. Infect. Dis. 28:1080-1085.
17. Griffith, D. E. 2007. Therapy of nontuberculous mycobacterial disease. Curr. Opin. Infect. Dis. 20:198-203.
18. Griffith, D. E., T. Aksamit, B. A. Brown-Elliott, A. Catanzaro, C. Daley, F. Gordin, S. M. Holland, R. Horsburgh, G. Huitt, M. F. Iademarco, M. Iseman, K. Olivier, S. Ruoss, C. F. von Reyn, R. J. Wallace, Jr., and K. Winthrop. 2007. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am. J. Respir. Crit. Care Med. 175:367-416.
19. Griffith, D. E., B. A. Brown-Elliott, S. Shepherd, J. McLarty, L. Griffith, and R. J. Wallace, Jr. 2005. Ethambutol ocular toxicity in treatment regimens for Mycobacterium avium complex lung disease. Am. J. Respir. Crit. Care Med. 172:250-253.
20. Gumbo, T. 2008. Integrating pharmacokinetics, pharmacodynamics and pharmacogenomics to predict outcomes in antibacterial therapy. Curr. Opin. Drug Discov. Devel. 11:32-42.
21. Gumbo, T., A. Louie, M. R. Deziel, and G. L. Drusano. 2005. Pharmacodynamic evidence that ciprofloxacin failure against tuberculosis is not due to poor microbial kill but to rapid emergence of resistance. Antimicrob. Agents Chemother. 49:3178-3181.
22. Gumbo, T., A. Louie, M. R. Deziel, W. Liu, L. M. Parsons, M. Salfinger, and G. L. Drusano. 2007. Concentration-dependent Mycobacterium tuberculosis killing and prevention of resistance by rifampin. Antimicrob. Agents Chemother. 51:3781-3788.
23. Gumbo, T., A. Louie, M. R. Deziel, L. M. Parsons, M. Salfinger, and G. L. Drusano. 2004. Selection of a moxifloxacin dose that suppresses drug resistance in Mycobacterium tuberculosis, by use of an in vitro pharmacodynamic infection model and mathematical modeling. J. Infect. Dis. 190:1642-1651.
24. Gumbo, T., A. Louie, W. Liu, P. G. Ambrose, S. M. Bhavnani, D. Brown, and G. L. Drusano. 2007. Isoniazid's bactericidal activity ceases because of the emergence of resistance, not depletion of Mycobacterium tuberculosis in the log phase of growth. J. Infect. Dis. 195:194-201.
25. Gumbo, T., C. S. Siyambalapitiyage Dona, C. Meek, and R. Leff. 2009. Pharmacokinetics-pharmacodynamics of pyrazinamide in a novel in vitro model of tuberculosis for sterilizing effect: A paradigm for faster assessment of new antituberculosis drugs. Antimicrob. Agents Chemother. 53:3197-3204.
26. Han, X. Y., J. J. Tarrand, R. Infante, K. L. Jacobson, and M. Truong. 2005. Clinical significance and epidemiologic analyses of Mycobacterium avium and Mycobacterium intracellulare among patients without AIDS. J. Clin. Microbiol. 43:4407-4412.
27. Hand, W. L., R. M. Boozer, and N. L. King-Thompson. 1985. Antibiotic uptake by alveolar macrophages of smokers. Antimicrob. Agents Chemother. 27:42-45.
28. Heifets, L. B., M. D. Iseman, and P. J. Lindholm-Levy. 1986. Ethambutol MICs and MBCs for Mycobacterium avium complex and Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 30:927-932.
29. Jayaram, R., S. Gaonkar, P. Kaur, B. L. Suresh, B. N. Mahesh, R. Jayashree, V. Nandi, S. Bharat, R. K. Shandil, E. Kantharaj, and V. Balasubramanian. 2003. Pharmacokinetics-pharmacodynamics of rifampin in an aerosol infection model of tuberculosis. Antimicrob. Agents Chemother. 47:2118-2124.
30. Jayaram, R., R. K. Shandil, S. Gaonkar, P. Kaur, B. L. Suresh, B. N. Mahesh, R. Jayashree, V. Nandi, S. Bharath, E. Kantharaj, and V. Balasubramanian. 2004. Isoniazid pharmacokinetics-pharmacodynamics in an aerosol infection model of tuberculosis. Antimicrob. Agents Chemother. 48:2951-2957.
31. Kasperbauer, S. H., and C. L. Daley. 2008. Diagnosis and treatment of infections due to Mycobacterium avium complex. Semin. Respir. Crit. Care Med. 29:569-576.
32. Kemper, C. A., D. Havlir, D. Haghighat, M. Dube, A. E. Bartok, J. P. Sison, Y. Yao, B. Yangco, J. M. Leedom, J. G. Tilles, et al. 1994. The individual microbiologic effect of three antimycobacterial agents, clofazimine, ethambutol, and rifampin, on Mycobacterium avium complex bacteremia in patients with AIDS. J. Infect. Dis. 170:157-164.
33. Kim, M.-K., and D. P. Nicolau. 2007. Aminoglycosides, p. 147-175. In C. H. Nightangle, P. G. Ambrose, G. L. Drusano, and T. Murakawa (ed.), Antimicrobial pharmacodynamics in theory and practice. Informa Healthcare USA, New York, NY.
34. Kobashi, Y., K. Yoshida, N. Miyashita, Y. Niki, and M. Oka. 2006. Relationship between clinical efficacy of treatment of pulmonary Mycobacterium avium complex disease and drug-sensitivity testing of Mycobacterium avium complex isolates. J. Infect. Chemother. 12:195-202.
35. Lee, C. S., D. C. Brater, J. G. Gambertoglio, and L. Z. Benet. 1980. Disposition kinetics of ethambutol in man. J. Pharmacokinet. Biopharm. 8:335-346.
36. Peloquin, C. A., A. E. Bulpitt, G. S. Jaresko, R. W. Jelliffe, J. M. Childs, and D. E. Nix. 1999. Pharmacokinetics of ethambutol under fasting conditions, with food, and with antacids. Antimicrob. Agents Chemother. 43:568-572.
37. Sbarbaro, J. A., and L. D. Hudson. 1974. High dose ethambutol; an oral alternate for intermittent chemotherapy. Am. Rev. Respir. Dis. 110:91-94.
38. Shandil, R. K., R. Jayaram, P. Kaur, S. Gaonkar, B. L. Suresh, B. N. Mahesh, R. Jayashree, V. Nandi, S. Bharath, and V. Balasubramanian. 2007. Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy. Antimicrob. Agents Chemother. 51:576-582.
39. Sison, J. P., Y. Yao, C. A. Kemper, J. R. Hamilton, E. Brummer, D. A. Stevens, and S. C. Deresinski. 1996. Treatment of Mycobacterium avium complex infection: do the results of in vitro susceptibility tests predict therapeutic outcome in humans? J. Infect. Dis. 173:677-683.
40. Sison, J. P., Y. Yao, C. A. Kemper, J. R. Hamilton, E. Brummer, D. A. Stevens, and S. C. Deresinski. 1996. Treatment of Mycobacterium avium complex infection: does the beige mouse model predict therapeutic outcome in humans? J. Infect. Dis. 173:750-753.
41. Srivastava, S., S. Musuka, C. Sherman, C. Meek, R. Leff, and T. Gumbo. 2010. Efflux-pump-derived multiple drug resistance to ethambutol monotherapy in Mycobacterium tuberculosis and the pharmacokinetics and pharmacodynamics of ethambutol. J. Infect. Dis. 201:1225-1231.
42. Tam, V. H., A. Louie, M. R. Deziel, W. Liu, R. Leary, and G. L. Drusano. 2005. Bacterial-population responses to drug-selective pressure: examination of garenoxacin's effect on Pseudomonas aeruginosa. J. Infect. Dis. 192:420-428.
43. Torriani, F. J., C. A. Behling, J. A. McCutchan, R. H. Haubrich, and D. V. Havlir. 1996. Disseminated Mycobacterium avium complex: correlation between blood and tissue burden. J. Infect. Dis. 173:942-949.
44. Turnidge, J., and D. L. Paterson. 2007. Setting and revising antibacterial susceptibility breakpoints. Clin. Microbiol. Rev. 20:391-408.
45. Zhu, M., W. J. Burman, J. R. Starke, J. J. Stambaugh, P. Steiner, A. E. Bulpitt, D. Ashkin, B. Auclair, S. E. Berning, R. W. Jelliffe, G. S. Jaresko, and C. A. Peloquin. 2004. Pharmacokinetics of ethambutol in children and adults with tuberculosis. Int. J. Tuber. Lung Dis. 8:1360-1367.